Healthcare - Biotechnology - NASDAQ - US
$ 26.5
-9.99 %
$ 172 M
Market Cap
-1.44
P/E
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.[ Read More ]
The intrinsic value of one TIL stock under the base case scenario is HIDDEN Compared to the current market price of 26.5 USD, Instil Bio, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart TIL
FINANCIALS
0
REVENUE
-159 M
OPERATING INCOME
-156 M
NET INCOME
-82 M
OPERATING CASH FLOW
41.1 M
INVESTING CASH FLOW
8.08 M
FINANCING CASH FLOW
0
REVENUE
-23.6 M
OPERATING INCOME
-23 M
NET INCOME
-20.1 M
OPERATING CASH FLOW
19.8 M
INVESTING CASH FLOW
159 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Instil Bio, Inc.
| Current Assets | 161 M |
| Cash & Short-Term Investments | 150 M |
| Receivables | 0 |
| Other Current Assets | 10.4 M |
| Non-Current Assets | 165 M |
| Long-Term Investments | 23.2 M |
| PP&E | 141 M |
| Other Non-Current Assets | 639 K |
| Current Liabilities | 10.6 M |
| Accounts Payable | 1.21 M |
| Short-Term Debt | 1.75 M |
| Other Current Liabilities | 7.6 M |
| Non-Current Liabilities | 89.2 M |
| Long-Term Debt | 84.3 M |
| Other Non-Current Liabilities | 4.94 M |
EFFICIENCY
Earnings Waterfall
Instil Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 4.76 M |
| Gross Profit | -4.76 M |
| Operating Expenses | 85.8 M |
| Operating Income | -159 M |
| Other Expenses | -3.08 M |
| Net Income | -156 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-69.12%
ROE
-47.93%
ROA
-51.80%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Instil Bio, Inc.
| Net Income | -156 M |
| Depreciation & Amortization | 4.76 M |
| Capital Expenditures | -20.7 M |
| Stock-Based Compensation | 18.2 M |
| Change in Working Capital | -9.02 M |
| Others | 51.1 M |
| Free Cash Flow | -103 M |
Wall Street Analysts Price Targets
Instil Bio, Inc.
Wall Street analysts predict an average 1-year price target for TIL of $87.8 , with forecasts ranging from a low of $11 to a high of $180 .
TIL Lowest Price Target
Wall Street Target
11 USD
-58.49%
TIL Average Price Target
Wall Street Target
87.8 USD
231.13%
TIL Highest Price Target
Wall Street Target
180 USD
579.25%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Instil Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 years ago
Mar 23, 2021
|
Bought 6 M USD
|
Vivo Capital IX, LLC
10 percent owner |
+ 300000
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 2.09 M USD
|
Shah Nimish P
Director |
+ 104640
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 2.34 M USD
|
Shah Nimish P
Director |
+ 116880
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 209 K USD
|
Shah Nimish P
Director |
+ 10470
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 968 K USD
|
Shah Nimish P
Director |
+ 48390
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 392 K USD
|
Shah Nimish P
Director |
+ 19620
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 6 M USD
|
Nielsen Jack
Director |
+ 300000
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 9 M USD
|
McGaughy R Kent Jr
Director |
+ 450000
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 9 M USD
|
Curative Ventures V LLC
10 percent owner |
+ 450000
|
20 USD |
|
3 years ago
Mar 23, 2021
|
Bought 9 M USD
|
Crouch Bronson
CEO and Chairman |
+ 450000
|
20 USD |
7. News
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.
globenewswire.com
- 1 week ago
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.
fool.com
- 1 month ago
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
benzinga.com
- 2 months ago
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
zacks.com
- 2 months ago
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).
globenewswire.com
- 2 months ago
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.
fool.com
- 2 months ago
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.
seekingalpha.com
- 2 months ago
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.
globenewswire.com
- 3 months ago
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M.
globenewswire.com
- 3 months ago
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
https://www.defenseworld.net
- 5 months ago
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update.
globenewswire.com
- 6 months ago
What Makes Instil Bio (TIL) a New Buy Stock
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 7 months ago
8. Profile Summary
Instil Bio, Inc. TIL
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 172 M
Dividend Yield
0.00%
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Contact
3963 Maple Avenue, Dallas, TX, 75219
https://instilbio.com
IPO Date
March 19, 2021
Employees
49
Officers
Dr. Sandeep Laumas M.D.
Chief Financial Officer & Chief Business Officer
Mr. Bronson Crouch
Chairman & Chief Executive Officer
Dr. Mark E. Dudley Ph.D.
Chief Scientific Officer